December 20, Dear Dr. Frieden:
|
|
- June Turner
- 5 years ago
- Views:
Transcription
1 December 20, 2011 The Honorable Thomas Frieden, MD, MPH Director, Centers for Disease Control and Prevention 1600 Clifton Road, NE. Mailstop A-07 Atlanta, GA Ref: [Docket No. CDC ]; Public Health Service Guideline for Reducing Transmission of Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) through Solid Organ Transplantation; September 21, 2011 Dear Dr. Frieden: On behalf of the 83 U.S. member eye bank organizations, the Eye Bank Association of America (EBAA) appreciates the opportunity to comment on the U.S. Public Health Service s Draft Guideline for Reducing Transmission of Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) through Solid Organ Transplantation. Our remarks are offered in the spirit of collegiality and cooperation, with the shared intent of harmonization and reciprocity of standards, assurance of quality and safety, and accountability. We applaud your efforts to update and expand the 1994 Guidelines for Preventing Transmission of Human Immunodeficiency Virus (HIV) through Transplantation of Human Tissue and Organs. Although we understand that this guidance is intended for solid organ transplantation and not corneal transplantation, it will indeed affect the corneal transplant community. To that end, the eye banking and corneal transplant community need assurance that any guidelines or regulations are consistent, reasonable and evidence-based. This guidance, as proposed, would specifically affect eye banks which share organ/tissue donors with the organ procurement organizations (OPOs). EBAA Background The EBAA is the world s oldest transplantation Association, established in 1961 by the American Academy of Ophthalmology (AAO). The EBAA first established medical standards and an accreditation program for inspection of eye banking organizations in 1980, and certification of technicians followed in the late 1980 s. The Association s standards and procedures have been used as a model for adaptation by other organizations in the United States, and other countries. They are reviewed and revised twice a year by a board of renowned corneal surgeons and certified technicians with expertise and extensive Page 1 of 12
2 experience in eye banking and then formally considered by the American Academy of Ophthalmology (AAO), which has endorsed them each year since The EBAA standards represent best practices in eye banking, are based on science specific to ocular tissue, and enjoy widespread recognition and acceptance. The Medical Advisory Board is responsible for promulgating EBAA medical standards, and a U.S. Food and Drug Administration (FDA) representative sits on the board. The EBAA Accreditation Board, also established in 1980, conducts inspections of eye bank members on a regular three year cycle or more often, as necessary. This includes Canadian banks and others outside the borders of the U.S. Eye banks which are accredited by the EBAA follow EBAA medical standards, and employ EBAA procedures which closely parallel and often exceed those of the FDA Good Tissue Practice regulations. All eye bank members of the EBAA are not-for-profit organizations whose mission is to recover and provide donated human eye tissue for sight restoring transplantation procedures, education, and research. Significant gains in ophthalmology are, in large part, due to donated ocular tissue provided by these eye banks. The EBAA strives to ensure the superior quality of banked human eyes through the adoption and implementation of stringent medical standards. On behalf of our member banks, we would like to offer these comments for consideration. The EBAA looks forward to working with the Centers for Disease Control and Prevention, located within the Department of Health and Human Services and our other transplant partners to ensure the safety of solid organs, ocular and other tissues provided for transplant. General Comments: Although this is a guidance document, its likely impact and acceptance will be akin to a regulatory standard:...intended for use by OPO staff, transplant staff including physicians, nurses, administrators and clinical coordinators; and laboratory staff responsible for testing and storing donor and recipient specimens; and persons responsible for developing, implementing, and evaluating infection prevention and control programs for organ procurement organizations and transplant centers. As such, its recommendations should be based on the highest level of evidence and consensus. Category 1 recommendations have even more potentially burdensome implications: For policymakers: recommendations may be adopted as policy or is current federal and/or state statutes, regulation or standards. This document fails to provide a reasonable estimate regarding the overall rate of confirmed transmission of HIV, HCV, and HBV from donor to recipient. Similarly, there is no projection of the anticipated clinical benefit in terms of reducing disease transmission should these recommendations be implemented. This data should provide threshold information on which to base recommendations and their absence undermines the argument in favor of necessary regulation. Page 2 of 12
3 The draft document views the practice of solid organ transplantation from the sole perspective of minimizing the risk of disease transmission of HIV, HCV, and HBV. Because transplantation of organs from HBV and HCV infected donors is accepted medical practice in situations where the recipients are informed and accept the risks of potential transmission, we suggest that the focus of the guidance should instead be on reduction of unintended donor disease transmission. The USPHS should be commended for attempting to maximize the number of deceased and living donor organs made available for transplant by avoiding exclusionary criteria and instead identifying risk groups and recommended donor and recipient interventions. However the EBAA is troubled by CDC s statement in the Background Section under Donor Screening: Currently, potential blood and tissue donors who have risk factors for bloodborne pathogen infection, such as HIV, are excluded from donating, since the availability of blood and tissue exceeds supply. In contrast, organs may be considered life-saving and since demand far exceeds demand, increased risk donors are not excluded but can be accepted by transplant centers if patients are informed of the risks involved and consent. This comment implies that acceptance of blood and tissue by donors deemed to be at increased risk would be unacceptable. Despite the claim that the proposed guidelines are intended for solid organ transplantation only, the CDC is effectively making new exclusionary criteria for blood and tissue donors. The draft guideline completely ignores the impact on survival of those with irreversible organ failure resulting from a potential reduction in the number of solid organ donors due to the recommended screening strategies outlined. It is well known that the discard rate of donor organs categorized as elevated risk is higher than those that are standard risk. (See Kucirka, LM et. al., Curr Opin Organ Transplant 2011 Apr; 16(2): ) It is therefore highly likely that this guideline, if implemented, will result in a net decrease in the number of available deceased donor organs and an increased number of deaths of waitlisted patients. Whether this would be offset by any reduction in infectious disease transmission is not addressed by the data provided. The transplantation community has been working to standardize the interview process and develop a uniform donor history questionnaire (UDHQ) with the goal of minimizing the risk of donor-derived transmissions. The lack of harmonization between the FDA s Guidance for Industry Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue- Based Products (HCT/Ps) and the factors associated with increased risk of recent HIV. HCV, and HBV identified in this PHS guidance in Table 3 would hamper these efforts to develop a UDHQ with uniform applicability for organs and tissue donors. The implementation of a different set of criteria for assessing increased risk for organ and eye/tissue donors will create a confusing dichotomy for organ and tissue procurement organizations working with shared donors. These guidelines do not address how an organization should handle this situation and whether this information would need to be disclosed to the corneal surgeon or surgical facility. Page 3 of 12
4 EBAA is concerned that this draft document is not a consensus document, since virtually all members of the Expert Panel and Review Committee members felt compelled to withdraw their names from the document due to a lack of a collaborative process and serious objections with methodology and conclusions. The final Expert Panel consisted of only four specialists in laboratory sciences and epidemiology employed by the CDC and the final Review Committee included only one external physician member with experience in transplantation. Under these circumstances, it is extremely misleading to state that any of the recommendations are supported by expert consensus. The CDC needs to re-engage the experts in organ transplantation and seek input from all stakeholders before the publication of a final Guidelines document. These guidelines if published in their current form will have serious ramifications, decreasing not only the number of donor organs that may be accepted by recipients or transplant surgeons, but they will also affect the evaluation of ocular and tissue donors, further reducing the supply of these tissues. Donor Risk Assessment Many of the recommendations in this section refer to interviewing individuals regarding their behaviors or that of family members that would increase risk for acquiring HIV, HBV or HCV. We agree that a thorough donor history is important in establishing the presence of risk factors that may be associated with a poor transplant outcome. For interviews to be effective, a standardized, validated questionnaire is essential, along with adequate training of personnel for its administration. Establishing a validated questionnaire is a critical area for research in the future, to assess the efficacy in both high- and low-risk donor populations. It is our understanding that the goal of the risk assessment is to provide guidance regarding optimal donor testing and utilization. The Category IB recommendations in this section are based on literature that did not include potential solid organ donors and may cause the loss of potential donors based on questions that have a poor predictive screening value. There is limited data to clearly inform the level of risk associated with potential answers. Without this data, it may be challenging for clinicians to understand whether an answer represents a risk of disease transmission that outweighs the potential benefit of using the organs. Donor Risk Assessment, Recommendation #4. The recommendation that the father and mother of a pediatric donor be interviewed about behaviors that may have placed them at risk for acquiring infections that may have been transmitted to their child is intrusive and could exacerbate the distress to the family at the time of death of a child. Furthermore, this recommendation does not specify the intended age group. As a Category I recommendation, it is likely to be incorporated into policy to the detriment of scarce pediatric donors and their families. We would instead propose that you harmonize with the FDA s Guidance for Industry Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), and Page 4 of 12
5 require screening of the birth mother when an infant is one month of age or less. The interview with the father should only be required if the interview with the mother is not possible. Donor Risk Assessment, Recommendation #5. The recommendation that children with any risk factors associated with increased probability of HIV, HCV, and HBV be identified as increased-risk is vague and unnecessary. By referring to children, it is assumed the authors mean potential pediatric donors. The risk factors for potential maternal transmission are covered in recommendations 4 and 6. This recommendation should be reworded as it would seem to apply to all potential donors adult and pediatric. Donor Risk Assessment, Recommendation #6. We are in general agreement with this recommendation that children 2 years of age born to mothers with HIV, HBV, or HCV infection or who meet increased risk criteria should also be identified as increased risk. However, this has important implications for potentially reducing the availability of organs from an extremely small pediatric donor pool, increasing the already high mortality for children waiting for transplants. We are concerned that the reference age differs from the FDA criteria for child donors and fails to mention the risk associated with breast-feeding in the preceding 12 months. The EBAA requests that you harmonize with the FDA s Guidance for Industry Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) which includes children 18 months of age or younger and children if breast-fed within the preceding 12 months. Donor Risk Assessment, Recommendation #7. We are in agreement with this recommendation, since hemodilution may result in false negative serological and NAT testing. This is current UNOS policy. Guidelines regarding the use of organs from both average risk and increased risk donors with negative but unreliable screens should be outlined. If organs are used, a standardized approach to quoting/communicating risk to potential recipients should be defined. Donor Screening General Comments: The EBAA has concerns with the recommendation that the most sensitive test available should always be used. The most sensitive test may not be the appropriate test in the organ donor setting when weighing risk/benefit, cost effectiveness and logistics of implementation. In fact, the opposite conclusion was reached following a recent joint consensus conference of transplant infectious disease experts (see Humar et al., Am J Transplant Apr; 10(4): , which is notably absent from your references). NAT testing will almost always be more sensitive than antigen or antigen/antibody testing, but may be less effective in this setting due to specificity issues or delays in obtaining results that might impact organ quality or result in donor loss. The most sensitive test may result in an extremely marginal increase in yield (i.e. HIV, RNA and NAT versus fourth generation HIV or Ag/AB screening) particularly when used in average risk populations, but at an extremely large increase in cost. We question the advisability of preference for the most sensitive test without regard to the Page 5 of 12
6 cost effectiveness or availability. Costs will likely be even higher in the setting of organ donation where STAT testing of individual donors (rather than less expensive batch minipool testing) is performed. The term available needs clarification as to whether this is locally or nationally available; or perhaps this should be replaced with licensed by the FDA. Further research is needed to assess the validity of screening tests results for HIV, HBV, and HCV in relevant populations to determine the best available test for increased and average risk donors. Donor Screening Recommendation #1. We believe this recommendation for serologic screening to be appropriate for all living or deceased potential organ donors. Donor Screening Recommendation #2. We agree that all living donors should undergo serologic screening for HIV, HCV, and HBV and NAT screening for HIV and HCV. NAT testing significantly reduces the window period of undetected infection before antibodies develop. Screening potential donors many months prior to the date of transplant could allow donation to proceed from a donor infected subsequent to that screening. However, we are concerned the recommendation to screen all potential live donors within seven days of the intended date of surgery may not be feasible. A seven day time period may not be adequate to obtain the results of these tests in time to inform decisions regarding the operation, particularly if a given donor is part of a multi patient chain. In a study by Kucirka, et al., Am J Transplant. Mar 2009; 9(3): , 45% of OPOs who perform NAT testing send the specimens to a different state where 24/7 NAT screening is available. We are concerned with the statement Test results should be obtained before organ recovery occurs, if feasible. In a living donor situation, organ procurement should not proceed without knowledge of serologic and NAT screening results. In an elective procedure, NAT screening should be performed sufficiently in advance to guarantee these results will be available to inform decisions regarding the transplantation or early treatment interventions. Donor Screening Recommendations #3 & 4. The rationale for obtaining universal HIV and HCV NAT testing on all deceased donors is to reduce the window period until serologic testing becomes positive. However there are concerns that universal NAT testing of low-risk donors may lead to increased false positive results and the unnecessary exclusion of suitable donors. The question remains whether expanding the donor pool through enhanced acceptance of NAT negative organs would balance or exceed the organ loss from false positive NAT results. Studies of average-risk donors are needed to model the benefits over the risks (donor loss from false positive tests). Clear standardized guidelines should be developed for interpretation and response to initial and confirmatory test results. Will NAT testing be discontinued when alternative testing becomes available, or will these fourth generation antigen/antibody tests (when FDA-licensed and available) add significantly to the screening costs? We are puzzled by the statement: NAT results should be obtained either before, if timing allows, or after procurement. Is it the intent of the authors that organ transplantation may occur prior to obtaining the results of NAT testing? If so, how will performing NAT impact the transmission of HIV and HCV to recipients with results not available prior to implantation? Page 6 of 12
7 Donor Screening Recommendations #5 &6. We support the recommendation to perform HBV NAT testing on deceased donors identified as being at increased risk or when behavioral risk factors cannot be determined. Once again studies are needed to model the risk/benefit of HBV NAT testing of increased-risk organ donors. Experience in the blood system suggests donors with HBV infection are less likely to have risk factors identified by the social/behavior questionnaire compared to HCV and HIV positive donors. Current criteria to identify increased risk donors have not been validated for utility in identifying incident HBV disease in the current vaccine era. The implementation of NAT for HBV has only recently been recommended in the blood system. Currently available FDA-licensed donor screening platforms are moving to trivalent NAT testing in Therefore, HBV NAT testing may be done on both average and increased-risk donor populations, despite the poor quality of incidence data in even high-risk populations. HBV viral loads in window period donor are often extremely low, creating greater problems in differentiating true positive from false positive results. If NAT testing for HBV is implemented, we agree that having results available after recovery and transplantation might positively impact recipient care as preemptive treatment with antiviral therapy might prevent or modify infection and clinical disease. We would propose adding a recommendation to provide targeted HBV immunizations to patients with organ failure at the time they are placed on the waitlist, to further reduce the risk for transmission of HBV by an infected donor. Donor Screening Recommendations #7. This recommendation requires clarification: Does it mean that one can use FDA-licensed diagnostic tests as opposed to assays licensed for donor screening for living and deceased donors? This would be a change in national policy, would not harmonize with the donor testing requirements for HCT/Ps, and would represent an off-label use of the former tests. Donor Screening Recommendations #8. We do not believe that transplantation should proceed without serologic results. NAT testing results received after transplantation would clearly not protect the recipient, although early treatment for HIV and HBV could be initiated once results are obtained. We suggest this recommendation be reworded as follows: NAT results for HIV, HBV, or HCV may be reported following organ transplantation in situations of life threatening illness where benefits of transplantation outweigh potential risks of infection transmission. Donor Screening Recommendations #9: We agree that all donor screening should be performed as outlined by the manufacturer. Page 7 of 12
8 Table 3 Comments: Sexual Contact: The EBAA believes that the risk factor of persons who have had sex with > 2 partners in the preceding 12 months sets the multi-partner threshold too low, impacts the younger donors heavily, and would lead to a large proportion of the donor population being classified as being at increased risk. This would result in the requirement for special informed consent from a large proportion of recipients, and could reduce the number of organs considered acceptable by potential recipients. A widow or divorcee who has entered into another committed relationship within the year would be considered to be in a higher risk category by this criterion. It should be noted that the Donor History Questionnaire for donors of blood and blood components determines sexual risk factors based on unsafe sexual contact or sexual contact with at-risk partners, without asking the specific number of sexual partners. It is doubtful that a proxy historian will know the private and intimate lives of their loved one and be able to accurately respond to this question. The quality of data supporting this recommendation is poor. A review of the data tables that accompany the proposed guidelines indicates this risk was not identified for all three of the viruses, and further that the studies evaluated risk based sexual partners in a six month (rather than a 12 month) time period and was much more impressive for a larger number of sexual contacts (50 lifetime partners or at least 10 in the six month time period). Modeling should be done as to the impact that this is likely to have on organ donation and transplantation. In light of universal serology and HIV and HCV NAT testing of donors, and the move towards trivalent NAT test kits, this overly conservative threshold does little to protect the recipient population. The eye bank community is concerned that labeling donors who were not monogamous in the past 12 months as being at increased risk of transmitting HIV, hepatitis B and hepatitis C, would unnecessarily decrease the number of corneal donors. Although this guidance is not intended for eye and tissue banks, the divergent standard would create communication and interpretation issues with shared donors. Donors identified as increased-risk for organ donation might not be referred to partner agencies, and even if referred, the Donor Coordinator may errantly rule out the donor based on the documented increased risk categorization. Although persons who have had sex with 2 partners in the preceding 12 months is not exclusionary criteria for HCT/Ps, would we ethically need to communicate this to our corneal surgeons when offering tissue for transplant? The EBAA strongly recommends that you eliminate this risk criterion. We accept all of the other bullets under sexual contact, as these are consistent with the FDA s eligibility determination for HCT/Ps. We praise the CDC for narrowing the time frames for risk behaviors to the preceding 12 months, as this would be more associated with recent acquisition of disease. Maternal transmission: We agree with restricting this to infants < 2 years old and birth to a mother infected with HIV, HBV or HCV. Parenteral injection of drugs in last 12 months: We agree with this recommendation. Page 8 of 12
9 Intranasal use of illicit drug in last 12 months: We do not agree with this recommendation. There is low to very low quality evidence associating use of cocaine or street drugs and bloodborne pathogen infection. Many of these studies were confounded by injection drug use. In light of the recommendations for universal serology and HIV and HCV NAT testing of all donors, and the move towards trivalent NAT test kits, the inclusion of this risk factor does little to protect the recipient population. This would result in the requirement for special informed consent and the additional requirement for HBV NAT testing. Illicit drug use was not associated with HBV in a corneal donor study (Sanchez, et. al., Eye Contact Lens. 2006; 32(2): ). The Retrovirus Epidemiology Donor Study (REDS), funded by the National Heart, Lung, and Blood Institute (NHLBI) did not find intranasal cocaine use to be an independent risk factor for HCV. Therefore, this question was eliminated from the uniform blood donor questionnaire. The lack of standardization with HCT/P exclusionary criteria will confound donor screeners for shared organ and tissue donors. Inmate in a correctional facility: The time limit of > 3 days harmonizes with the HCT/P exclusionary criteria. We agree that for potential donors who are have been released from a correctional institution for more than 12 months prior to donation are not at increased risk for recent infection. STD treatment in the preceding 12 months: We agree with this recommendation. Hemodialysis in the preceding 12 months: There was low quality evidence which found an association between hemodialysis and HCV infection. Current CDC recommended practices include infection control procedures and monthly ALT testing and serologic testing for HCV every six months to monitor for the occurrence of new HCV infection among chronic hemodialysis patients. With the CDC recommendation for universal serology and HCV NAT testing of all living and deceased organ donors, the inclusion of this risk factor does little to protect the recipient population. A person on hemodialysis is not considered to be at increased risk for HCT/P or blood donation, so this risk criterion should be eliminated. Persons who have immigrated to the US in last 12 months from high or intermediate prevalence area (HBV only): We do not support this recommendation. By your own admission, this review found very low quality evidence to suggest a relationship between HBV and an individual s race, ethnicity, or national origin. The grade of evidence specifically for national origin/birthplace was also rated very low. In a general population study, acute HBV was not associated with birth in an area with a high endemic rate of HBV or having a household contact with someone who was born in an endemic area (Reference 116). More specific information is needed on geographic regions considered high incidence areas. Risk factors vary geographically and temporally and can change quickly in an outbreak setting. Coordinated vigilance would be necessary to modify this guidance in a timely manner when new information becomes available. Page 9 of 12
10 HBV-Infected Donors and Transplantation HCV-Infected Donors and Transplantation Eye banks do not transplant corneas from HBV- and HCV-infected donors and therefore we offer no specific comments to these recommendations. We are in agreement with the need for informed consent and risk reduction strategies. Recipient Informed Consent The EBAA is in agreement that counseling and informed consent should occur at the time of candidate listing and again at the time of organ offer, balancing the risk of donor-derived infection against the risk of remaining on the waiting list. We recommend the development of a standardized approach to the consenting process, with certain defined key elements to be included. We are not in support of requiring a separate informed consent for vessel conduits. This would be confusing to patients and it is often unknown whether or not an additional vessel will be required until the surgery is underway. The EBAA recommends this be incorporated into the informed consent discussion. Recipient Testing We suggest rewording Recommendation # 1 as follows: Baseline serologic testing for which recipients are previously negative should be repeated at the time of admission to undergo transplantation, but prior to implantation of the organ. We are in agreement with the post-transplant recipient testing recommendations, which follow a modified occupational exposure testing schedule. Donor and Recipient Specimen Collection and Storage Donor and Recipient Specimen Collection and Storage, Recommendation #1. OPOs may be unable to obtain both serum and EDTA plasma specimens, due to specimen volume or hemodilution, with potential regulatory consequences. Therefore this recommendation should be reworded to state that whenever possible, a separate EDTA tube should be obtained in addition to usual serum specimens, as an EDTA specimen is preferred for NAT. Donor and Recipient Specimen Collection and Storage, Recommendation #2. It is current OPTN/UNOS policy and AOPO best practice to archive deceased donor blood samples for 10 years, but there is no current mandate for storage of living donor samples. This will lead to increased costs, storage capacity issues, and infrastructure requirements. It is not feasible to require the separation of samples into aliquots, and this should be considered when storage capacity and specimen volume permits, as stated in Recommendation #3. Page 10 of 12
11 Donor and Recipient Specimen Collection and Storage, Recommendation #3. This recommendation restates the separation of EDTA plasma into multiple aliquots. This wording is much clearer and is more conditional in terms of stating when capacity exists and when there is adequate specimen volume. We recommend that you replace recommendation #2 with recommendation #3. Donor and Recipient Specimen Collection and Storage, Recommendation #4. The EBAA is in agreement that storage of archival serum or plasma specimens should be according to the test manufacturer s package insert (-20 C or colder). Donor and Recipient Specimen Collection and Storage, Recommendation #5. This recommendation creates an archival bank of living donors which would require the development of infrastructure and storage capacity by transplant centers. Ascertaining the infectious status of a living donor years after transplantation should be relatively easy and therefore a significantly shorter period of storage should be adequate. A living donor provides a directed donation to only one recipient, so this does little to enhance the safety of multiple organ and tissue recipients. Donor and Recipient Specimen Collection and Storage, Recommendation #6. The EBAA is in agreement that the FDA plasma dilution algorithm and calculation method should be utilized to determine if a specimen is acceptable for infectious disease testing. This is current OPO policy. Donor and Recipient Specimen Collection and Storage, Recommendation #7. The EBAA is in support of the recommendation to quarantine any stored blood vessels from a donor found to be HIV, HBV, or HCV infected, and either utilized only for research purposes or destroyed. Tracking and Reporting of HIV, HBV, and HCV Much of what is being recommended in this section has already been adopted by the transplant community and is part of current clinical practice and policy. The EBAA is supportive of these existing practices and appreciate the current document reflecting these practices. Tracking and Reporting of HIV, HBV, and HCV, Recommendation #1. The EBAA supports the requirement for the OPO to report to the transplant center if information becomes available that a deceased donor was infected with HIV, HCV, HBV, or any other potentially transmissible agent. This is consistent with current practice. Tracking and Reporting of HIV, HBV, and HCV, Recommendation #2. The EBAA supports the recommendation that information obtained by the transplant center that an organ transplant recipient has acquired a new infection with HIV, HBC or HCV that might be donor derived should be reported back to the OPTN. HIV, HBV, or HCV infection in a transplant recipient which occurs years after transplantation should be reported to the appropriate local and state health departments, but not to OPTN. Tracking and Reporting of HIV, HBV, and HCV, Recommendation #3. The EBAA supports the collection of nationally aggregated data on pre- and post-transplant bloodborne pathogen screening assessments but this recommendation does not specify who would be responsible for collecting and analyzing this data. Would this remain under the purview of DTAC? Page 11 of 12
12 Tracking and Reporting of HIV, HBV, and HCV, Recommendations #4 and #5. The EBAA is in agreement with the tracking and records requirement for organs and blood vessels. This is already OPTN policy. Tracking and Reporting of HIV, HBV, and HCV, Recommendation #6. The recommendation for reporting a recipient who is found to be newly infected with HIV, HBV, or HCV post-transplant is previously covered in recommendation #2, so this may be deleted. Tracking and Reporting of HIV, HBV, and HCV, Recommendations #7 - #12. The EBAA is in agreement with these reporting requirements. Conclusion The Eye Bank Association of America (EBAA) appreciates this opportunity to comment on the U.S. Public Health Service s Draft Guideline for Reducing Transmission of Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) through Solid Organ Transplantation. Our remarks are offered in the spirit of collegiality and cooperation, with the shared intent of harmonization and reciprocity of standards, assurance of quality and safety, and accountability. These guidelines, if finalized in their current form, are likely to have significant consequences for the transplant community and the costs of transplantation. For this reason we urge the PHS to revise this document with broad representation and meaningful input from the transplant community, the American Society of Transplant Surgeons (ASTS), the American Society of Transplantation (AST), the Association of Organ Procurement Organizations (AOPO), and NATCO, the Organization for Transplant Professionals. All stakeholders who can be affected should be part of the development process, including the American Association of Tissue Banks (AATB) and the Eye Bank Association of America (EBAA). We therefore recommend a delay in finalization of these guidelines until these issues can be properly addressed. Sincerely, Patricia Aiken O Neill, Esq. President and CEO Eye Bank Association of America Page 12 of 12
[Submitted Electronically]
[Submitted Electronically] Dr. Matthew J. Kuehnert, Director Office of Blood, Organ, and Other Tissue Safety Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious
More informationReport on the Transplantation Transmission Sentinel Network (TTSN)
Report on the Transplantation Transmission Sentinel Network (TTSN) CATB Session - AATB s 31st Annual Meeting, Boston September 15, 2007 Scott Brubaker, CTBS AATB Representative, TTSN Advisory Group TTSN
More informationCurrent Infectious Disease Screening for the Live Organ Donor
2013 Public Health and Safety Guidelines for reducing HIV, HBV and HCV Transmission Though Organ Transplantation: Implications for Counseling and Disclosure Dianne LaPointe Rudow DNP, ANP-BC, CCTC Director
More informationUDHQ Project Overview and Update 7 May 2012
Introduction Organ, tissue, and eye (OTE) donation and transplantation professionals have long understood the value of collecting medical and behavioral history information on potential donors to assess
More information23 November Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
23 November 2016 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA-2016-N-1502,
More informationHot Topics in Tissue Safety
Hot Topics in Tissue Safety 37 th Annual AATB Meeting National Harbor, Maryland 03 October 2013 Scott A. Brubaker, CTBS Chief Policy Officer PHS Guideline for Reducing Human Immunodeficiency Virus, Hepatitis
More informationGuidance for Industry
Guidance for Industry Advisement for the Use of Gen-Probe Procleix Ultrio Plus Assay for NAT Testing on Cadaveric Donors Release Date: 08/03/14 American Medical Education and Research Association 4757
More informationThe TTSN - A Collaborative Biovigilance System
The TTSN - A Collaborative Biovigilance System 5th World Congress on Tissue Banking 12th International Conference of the APASTB Kuala Lumpur, Malaysia June 4, 2008 Scott A. Brubaker, CTBS American Association
More informationJune 8, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
June 8, 2018 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA 2016 D 0545,
More information2.0 MINIMUM PROCUREMENT STANDARDS FOR AN ORGAN PROCUREMENT ORGANIZATION (OPO)
2.0 MINIMUM PROCUREMENT STANDARDS FOR AN ORGAN PROCUREMENT ORGANIZATION (OPO) In order to maximize the gift of donation and optimize recipient outcomes and safety, the Organ Procurement Organization (OPO)
More informationQSEAL Recovered Plasma Specification
QSEAL Recovered Plasma Specification Background The is part of a series of standards that comprise the Plasma Protein Therapeutics Association (PPTA) QSEAL Standards Program. PPTA's Voluntary Standards
More informationAchieving Consensus on Increased Risk Donors to Improve Access to Organ Transplantation Executive Summary
Achieving Consensus on Increased Risk Donors to Improve Access to Organ Transplantation Executive Summary Introduction To address the current shortage of organs for transplantation, (114,651 candidates
More informationPatient Name: MRN: DOB: Treatment Location:
Page 1 of 5 I. TO (Required) This Section is required to be completed by all patients who undergo kidney transplant surgery. I hereby consent to and authorize Dr. and his/her assistant(s), including supervised
More informationIncreased Risk Donors for Organ Transplantation
A Tool Kit to Assist Transplant Programs in the Use of Increased Risk Donors for Organ Transplantation February 2016 Table of Contents Table of Contents... 2 1.0 Increased Risk Donor Tool Kit... 3 1.1
More informationInfectious Disease Considerations in Organ Donation. Nikole A Neidlinger MD FACS Chief Medical Officer
Infectious Disease Considerations in Organ Donation Nikole A Neidlinger MD FACS Chief Medical Officer Screening Donors and Infectious Disease considerations: Deceased Donor Screening Donors at increased
More informationGuidance for Industry
Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately
More informationFebruary 3, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
February 3, 2014 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 ATTN: Leslie Kux, Assistant Commissioner for Policy Ref: [Docket No.
More informationDHMH Activities toward Implementing Requirements of Md. Code Ann., Health-General , Hepatitis C Prevention and Control within Maryland
DHMH Activities toward Implementing Requirements of Md. Code Ann., Health-General 18-1001, Hepatitis C Prevention and Control within Maryland Submitted by: Maryland Department of Health and Mental Hygiene
More informationImproving Utilization of Organs from Increased Risk Donors. Matthew J. Kuehnert, MD CDC
Improving Utilization of Organs from Increased Risk Donors Matthew J. Kuehnert, MD CDC Conflict of Interest Disclosure I have no relevant financial relationships to disclose. 2016 AST Improving Utilization
More informationAd Hoc Disease Transmission Advisory Committee Report
Ad Hoc Disease Transmission Advisory Committee Report OPTN/UNOS Board of Directors Meeting Dr. Michael Green, MD, MPH, Chair Dr. Daniel Kaul, MD, Vice Chair June 23-24, 2014 PHS Guideline for Reducing
More informationCDC s Position Protect Patients Against Preventable Harm from Improper Use of Single-dose/Single-use Vials
Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases Division of Healthcare Quality Promotion Single-dose/Single-use Vial Position and Messages May 2,
More informationWORLD HEALTH ORGANIZATION. Human organ and tissue transplantation
WORLD HEALTH ORGANIZATION EXECUTIVE BOARD EB113/14 113th Session 27 November 2003 Provisional agenda item 3.17 Human organ and tissue transplantation Report by the Secretariat 1. At its 112th session in
More informationThe DTAC News CONTENTS WELCOME. From the OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee
The DTAC News From the OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee FIRST EDITION FEBRUARY, 2010 Welcome to the first edition of the DTAC News. This newsletter is brought to you by the OPTN/UNOS
More informationVersion for the Silent Procedure 29 April Agenda item January Hepatitis
Version for the Silent Procedure 29 April 2014 134th session EB134.R18 Agenda item 10.5 25 January 2014 Hepatitis The Executive Board, Having considered the report on hepatitis, 1 RECOMMENDS to the Sixty-seventh
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationWorking Group Practices and Composition
November 26, 2018 Tickborne Disease Working Group Office of the Assistant Secretary for Health U.S. Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201 Dear Tickborne
More informationNATIONAL BLOOD TRANSFUSION SERVICES STRATEGY
FEDERAL DEMOCRATIC REPUBLIC OF ETHIOPIA MINISTRY OF HEALTH NATIONAL BLOOD TRANSFUSION SERVICES STRATEGY February 2005 Addis Ababa Ethiopia Acknowledgement The Ministry of Health of the Federal Democratic
More informationRe: Draft Guideline for Prescribing Opioids for Chronic Pain, 2016 [CDC ]
American Cancer Society Cancer Action Network 555 11 th Street, NW Suite 300 Washington, DC 20004 202.661.5700 www.acscan.org January 12, 2016 Tom Frieden, M.D., M.P.H. Director, Centers for Disease Control
More informationUser Instructions Allogeneic HPC, Apheresis and HPC, Marrow Donor History Questionnaire. Table of Contents
User Instructions Allogeneic HPC, Apheresis and HPC, Marrow Donor History Questionnaire Table of Contents Purpose Introduction Capture Questions Methods of Administration DHQ Materials - Structure and
More informationChanging eligibility criteria for MSM: The Canadian Perspective
Changing eligibility criteria for MSM: The Canadian Perspective Mindy Goldman MD Canadian Blood Services ASFA & WAA Joint Meeting, San Francisco April 4, 2014 Outline - Historical background - International
More informationCase 1. FDA, Legal, and EBAA Medical Standards Panel. Case 1. Case 1 6/25/2012. Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies
Case 1 FDA, Legal, and EBAA Medical Standards Panel Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Medical Directors Symposium Eye Bank Association of America Annual Meeting 47 y/o
More informationHICPAC Recommendation Categorization Update Workgroup: Public Comment Summary and Finalization
HICPAC Categorization Update Workgroup: Public Comment Summary and Finalization Deborah Yokoe and Daniel Diekema, Workgroup Co-Chairs HICPAC Presentation, November 2018 Disclaimer: The findings and conclusions
More informationCenters for Disease Control and Prevention. Recommendations for Providers Counseling Male Patients and
This document is scheduled to be published in the Federal Register on 12/02/2014 and available online at http://federalregister.gov/a/2014-27814, and on FDsys.gov BILLING CODE: 4163-18-P DEPARTMENT OF
More informationHepatitis B and C Overview, Outbreaks, and Recommendations. Viral Hepatitis Language. Types of Viral Hepatitis 7/1/2013
Hepatitis B and C Overview, Outbreaks, and Recommendations Elizabeth Lawlor, MS Healthy Kansans living in safe and sustainable environments. Viral Hepatitis Language Acute infection is when the infection
More informationWORLD HEALTH ORGANIZATION. Smallpox eradication: destruction of Variola virus stocks
WORLD HEALTH ORGANIZATION EXECUTIVE BOARD EB111/5 111th Session 23 December 2002 Provisional agenda item 5.3 Smallpox eradication: destruction of Variola virus stocks Report by the Secretariat 1. The WHO
More informationJuly 14, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
July 14, 2015 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA-2015-D-1211
More informationHepatitis C Best Practice Guidelines For Local Health Departments
Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have
More informationOpportunities for Organ Donor Intervention Research
Opportunities for Organ Donor Intervention Research Saving Lives by Improving the Quality and Quantity of Organs for Transplantation Webinar October 19, 2017 Committee Roster Committee on Issues in Organ
More informationHepatitis C January 26, 2018
Hepatitis C January 26, 2018 Case Investigation Guidelines Contents A. Purpose...2 B. Case Definitions...2 a. Acute Hepatitis C (2016...2 b. Chronic Hepatitis C (2016)...3 c. Perinatal Hepatitis C (2017
More informationGeneral Assembly. United Nations A/63/152/Add.1
United Nations General Assembly Distr.: General 8 May 2009 Original: English Sixty-third session Agenda items 41 and 124 Implementation of the Declaration of Commitment on HIV/AIDS and the Political Declaration
More informationUSER INSTRUCTIONS HPC, Cord Blood Donor History Questionnaire. Table of Contents
Page 1 of 9 USER INSTRUCTIONS HPC, Cord Blood Donor History Questionnaire Table of Contents Purpose Introduction Capture Questions Methods of Administration DHQ Materials Structure and Content Reformatting
More informationSeptember 10, To Whom It May Concern:
September 10, 2018 Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-1691-P P.O. Box 8010, Baltimore, MD 21244-8010 RE: CMS-1691-P Medicare Program; End-Stage
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationUpdate: ACIP Recommendations for Hepatitis B Vaccination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Update: ACIP Recommendations for Hepatitis B Vaccination Sarah Schillie, MD, MPH, MBA Summit for the Elimination of Hepatitis B and
More informationPrimary Care Services for blood borne viral hepatitis prevention, treatment and care
Primary Care Services for blood borne viral hepatitis prevention, treatment and care Author: Josie Smith, Marion Lyons Page 1 of 13 October 2006 Status : Final Contents: Page: Executive Summary 3 Introduction
More informationRE: Proposed Decision Memo for Screening for Hepatitis C Virus (HCV) in Adults (CAG-00436N)
April 2, 2014 Tamara Syrek Jensen, JD Acting Director Coverage and Analysis Group Center for Clinical Standards and Quality Centers for Medicare and Medicaid Services U.S. Department of Health and Human
More informationGuidance for Industry
Guidance for Industry Revised Recommendations for Donor and Product Management Based on Screening Tests for Syphilis DRAFT GUIDANCE This document is being distributed for comment purposes only. Submit
More informationJuventas SHARING LIFE CONSENT FOR PLASMA INFUSION
Juventas SHARING LIFE Print Name Date of Birth CONSENT FOR PLASMA INFUSION To the Patient or Guardian of the Patient: The purpose of this document is to provide written information as of (month and day),
More informationAdvisory Committee: A Report to the UNOS Board
Ad Hoc Disease Transmission Advisory Committee: A Report to the UNOS Board Emily A. Blumberg, MD Chair, /UNOS DTAC Shandie Covington UNOS Staff Liaison, DTAC June 28-29, 2011 Richmond, Virginia DTAC Action
More informationGuidance for ABO Subtyping Organ Donors for Blood Groups A and AB
Public Comment Proposal Guidance for ABO Subtyping Organ Donors for Blood Groups A and AB OPTN/UNOS Operations and Safety Committee Prepared by: Susan Tlusty UNOS Policy Department Contents Executive Summary
More informationAIDS, HIV, and Hepatitis B. To outline a plan for the prevention of exposure of hospital personnel to patients with AIDS, HIV, or Hepatitis B.
Audience: Purpose: Policy: AIDS, HIV, and Hepatitis B All personnel in the. To outline a plan for the prevention of exposure of hospital personnel to patients with AIDS, HIV, or Hepatitis B. The University
More informationMaximizing Cornea and Tissue Donation through Specimen Quality
Maximizing Cornea and Tissue Donation through Specimen Quality Robert W. Bresler, Sydney D. Gastreich, Elias G. Koulouriotis, Linda S. Martin, Susan Diane Brockmeier, Chak-Sum Ho, PhD Abstract Purpose:
More informationTRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING October2010. Issue Summary
TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING 28-29October2010 Issue Summary Informational Topic: FDA s Geographic Donor Deferral Policy to Reduce the Possible Risk of Transmission
More informationProposed Data Collection Submitted for Public Comment and. AGENCY: Centers for Disease Control and Prevention (CDC),
This document is scheduled to be published in the Federal Register on 03/13/2018 and available online at https://federalregister.gov/d/2018-05000, and on FDsys.gov BILLING CODE 4163-18-P DEPARTMENT OF
More informationHormonal contraception and HIV risk
Hormonal contraception and HIV risk Jared Baeten, MD, PhD Departments of Global Health, Medicine, and Epidemiology, University of Washington On behalf of the ECHO Consortium HPTN Annual Meeting Washington
More informationpatients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead:
CONTROLLED DOCUMENT Procedure for the management of patients with blood borne viruses CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationOPTN/UNOS Membership and Professional Standards Committee (MPSC) Meeting Summary October 25-27, 2016 Chicago, Illinois
OPTN/UNOS Membership and Professional Standards Committee (MPSC) Meeting Summary October 25-27, 2016 Chicago, Illinois Jeffrey Orlowski, Chair Matthew Cooper, M.D., Vice Chair Discussions of the full committee
More informationThe cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets
More informationPublic Health, Infections and Transplantation
Public Health, Infections and Transplantation Dr Kerry Chant Chief Health Officer & Deputy Director General Population and Public Health NSW Ministry of Health May2014 Public Health Infection and Transplantation
More informationRISK OF DISEASE TRANSMISSION FROM ORGAN DONORS PATIENT INFORMATION GUIDE
Receiving an organ transplant carries many risks, including the risk of getting a disease from the June 2017 donor. This is true for every organ we transplant. BC Transplant makes every effort to minimize
More informationProcess or performance improvement is often discussed
Process Improvement in Transfusion Medicine Ongoing efforts to decrease costs in the clinical laboratory make continuous process improvement especially important in difficult economic times. Process improvement
More informationMedicare Physician Fee Schedule Final Rule for CY 2018 Appropriate Use Criteria for Advanced Diagnostic Imaging Services Summary
Medicare Physician Fee Schedule Final Rule for CY 2018 Appropriate Use Criteria for Advanced Diagnostic Imaging Services Summary Background and Overview The Protecting Access to Medicare Act of 2014 included
More informationMinnesota Administrative Uniformity Committee (AUC) Mission Statement, History and Governing Principles. June 2014
Mission Statement, History and Governing Principles 1. Definitions June 2014 For purposes of this document, the following definitions apply: 1.1. "Group purchaser" Group purchaser has the meaning given
More informationChapter 5 Serology Testing
Chapter 5 Serology Testing 49 50 This page intentionally left blank. Diagnostic Tests for Hepatitis B Virus (HBV) Diagnosis of HBV infection (acute vs. chronic) is based on clinical, laboratory, and epidemiologic
More informationThe New Kidney Allocation System (KAS) Frequently Asked Questions
The New Kidney Allocation System (KAS) Frequently Asked Questions Contents General: The Need for the New System and Key Implementation Details... 4 Why was the newly revised KAS necessary?... 4 What were
More information4.6. How to test - testing strategy HCV. Decision-making tables PICO 4
4.6. How to test - testing strategy HCV Decision-making tables PICO 4 Testing strategy to ascertain exposure to HCV: Among persons identified for hepatitis C testing, what is the best testing strategy
More informationNIDA Rationale Clean 1 09/17/06
Rationale for Modifications to the 2001 National Institute on Drug Abuse Policy on Counseling and Testing for HIV/AIDS and other Infectious Diseases (NOT-DA-01-001). This document identifies and provides
More informationMaryland State Department of Education Maryland Department of Health and Mental Hygiene Maryland State School Health Council
Maryland State Department of Education Maryland Department of Health and Mental Hygiene Maryland State School Health Council MARYLAND STATE SCHOOL HEALTH SERVICES GUIDELINES Management of Students with
More information2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies
2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1
More informationDeveloping a Target Product Profile for a Preventive HIV Vaccine
Developing a Target Product Profile for a Preventive HIV Vaccine Topics to be Covered Overview of TPPs What are they? What is the purpose and benefit of using a TPP? What is usually in a TPP? What are
More informationSIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item April Viral hepatitis. Report by the Secretariat
SIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item 12.17 16 April 2009 Viral hepatitis Report by the Secretariat THE DISEASES AND BURDEN 1. The group of viruses that cause acute and/or chronic
More informationImplementation: Public Hearing: Request for Comments (FDA-2017-N-6502)
March 16, 2018 via online submission: www.regulations.gov The Honorable Scott Gottlieb Commissioner Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Opioid Policy Steering
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #400 (NQF 3059): One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY
More informationHEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38
2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally
More informationOrgan Procurement and Transplantation Network
OPTN Organ Procurement and Transplantation Network POLICIES This document provides the policy language approved by the OPTN/UNOS Board at its meeting in June 2015 as part of the Operations and Safety Committee
More informationWorld Health Organization. A Sustainable Health Sector
World Health Organization A Sustainable Health Sector Response to HIV Global Health Sector Strategy for HIV/AIDS 2011-2015 (DRAFT OUTLINE FOR CONSULTATION) Version 2.1 15 July 2010 15 July 2010 1 GLOBAL
More informationA. Anti-HIV-1/2, HIV NAT Lookback: for those identified blood and blood components collected:
PURPOSE: MATERIALS: To outline a procedure for removing, recalling and/or correcting blood products that do not meet the requirements of the FDA, AABB, or the blood center. Recall/Market Withdrawal Form
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationPreparing For Pandemic Influenza: What the CDC and HHS Recommend You Can Do
Preparing For Pandemic Influenza: What the CDC and HHS Recommend You Can Do Based on current data and information from the Centers for Disease Control (CDC) and the U.S. Department Health and Human Services
More information10.2 Summary of the Votes and Considerations for Policy
CEPAC Voting and Policy Implications Summary Supplemental Screening for Women with Dense Breast Tissue December 13, 2013 The last CEPAC meeting addressed the comparative clinical effectiveness and value
More informationRe: Docket No. FDA D Presenting Risk Information in Prescription Drug and Medical Device Promotion
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org August 25, 2009 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationThe Art and Science of Increasing Authorization to Donation
The Art and Science of Increasing Authorization to Donation OPO Metrics: The Good, The Bad, and The Maybe Charlotte Arrington, MPH Arbor Research Collaborative for Health Alan Leichtman, MD University
More informationHepatitis C Virus (HCV)
Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are
More informationOutbreak Investigation Guidance for Vectorborne Diseases
COMMUNICABLE DISEASE OUTBREAK MANUAL New Jersey s Public Health Response APPENDIX T3: EXTENDED GUIDANCE Outbreak Investigation Guidance for Vectorborne Diseases As per N.J.A.C. 8:57, viruses that are transmitted
More informationManagement of Acute HCV Infection
Management of Acute HCV Infection This section provides guidance on the diagnosis and medical management of acute HCV infection, which is defined as presenting within 6 months of the exposure. During this
More informationOPTN/UNOS Ethics Committee Report to the Board of Directors June 1-2, 2015 Atlanta, GA. Peter Reese, MD, Chair Elisa Gordon, PhD, MPH, Vice Chair
OPTN/UNOS Ethics Committee Report to the Board of Directors June 1-2, 2015 Atlanta, GA Peter Reese, MD, Chair Elisa Gordon, PhD, MPH, Vice Chair Contents Action Items... 2 1. Ethical Principles to be Considered
More informationStrategies for Federal Agencies
Confronting Pain Management and the Opioid Epidemic Strategies for Federal Agencies Over the past 25 years, the United States has experienced a dramatic increase in deaths from opioid overdose, opioid
More informationTA L K I N G A B O U T T R A N S P L A N TAT I O N UNOS. Facts and. Figures
TA L K I N G A B O U T T R A N S P L A N TAT I O N UNOS Facts and Figures U N I T E D N E T W O R K F O R O R G A N S H A R I N G United Network for Organ Sharing The United Network for Organ Sharing (UNOS)
More informationUser Instructions Allogeneic HPC, Apheresis and HPC, Marrow Donor History Questionnaire. Table of Contents
User Instructions Allogeneic HPC, Apheresis and HPC, Marrow Donor History Questionnaire Table of Contents Purpose Introduction Methods of Administration DHQ Materials - Structure and Content Reformatting
More informationBill 18 - The Testing of Bodily Fluids and Disclosure Act
Paramedic Association of Manitoba Submission to Standing Committee on Social and Economic Development Bill 18 - The Testing of Bodily Fluids and Disclosure Act April 28, 2008 By means of introduction,
More information2.1 HIV antibody tests
Over 100 different kinds of HIV test are currently available worldwide. More are likely to become available in the future. The choice of test depends on factors including laboratory requirements, how easy
More information10:15-10:50 Welcome and Update from Regional Councillor, Matthew Cooper, MD Non-Discussion Agenda (includes minutes for voting preparation)
DRAFT AGENDA OVERVIEW Region 2 Meeting Gift of Life Donor Program 401 N 3 rd Street, Philadelphia, PA 19123 September 14, 2018 (Note: All times except the start time are approximate. Actual times will
More informationImplementation of the Stem Cell Therapeutic and Research Act of 2005
Implementation of the Stem Cell Therapeutic and Research Act of 2005 The 6 th Annual Somatic Cell Therapy Symposium Bethesda, MD September 26, 2006 James F. Burdick, M.D. U.S. Department of Health and
More informationFramework on the feedback of health-related findings in research March 2014
Framework on the feedback of health-related findings in research March 2014 Summary Scope and background In the course of a study involving human participants, researchers may make a finding that has potential
More informationHealthcare-Related Outbreaks of Hepatitis B and C in the United States
Healthcare-Related Outbreaks of Hepatitis B and C in the United States Ian T. Williams, PhD, MS Epidemiology Branch Division of Viral Hepatitis National Center for Infectious Diseases Centers for Disease
More informationZika Virus. Report to the Standing Committee on Health. Dr. Graham Sher Chief Executive Officer, Canadian Blood Services
Dr. Graham Sher Chief Executive Officer, Services Dr. Dana Devine Chief Medical and Scientific Officer, Services Services Services is an arm s-length organization within the larger health-care system of
More informationINITIAL EVALUATION AND MANAGEMENT FOLLOWING EXPOSURE TO BLOOD OR BODY FLUIDS
Page 1 of 11 Original Date of Issue: June 1991 Reviewed 2/96 5/97 11/98 11/99 5/01 5/02 12/05 Revised 9/95 5/97 5/00 7/02 3/06 6/08 6/10 The following are the procedures to be followed when a person sustains
More informationAntiretroviral therapy for adults and adolescents KEY MESSAGES. HIV/AIDS Department BACKGROUND
KEY MESSAGES New WHO Recommendations: Antiretroviral therapy for adults and adolescents The World Health Organization (WHO) is revising its guidelines on antiretroviral therapy (ART) for adults and adolescents.
More information